Combination therapy for head and neck cancer
Treatments studied
Part of Bones, joints & muscles, Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests a combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) plus targeted radiation before surgery for head and neck cancer. The goal is to see if this approach can shrink the tumor or help the surgery be more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of head and neck cancer (in the mouth, voice box, throat, or lower throat) that can be removed with surgery and has not spread to distant organs.
- Your cancer is HPV-negative (a lab test result).
- Your tumor has a protein called PD-L1 at a certain level (tested by your doctor).
- You are willing to provide a blood sample and a small piece of tumor tissue before treatment and again at surgery.
- You are generally healthy enough to carry out daily activities (performance status 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial compares giving immunotherapy alone versus immunotherapy plus focused radiation before surgery for head and neck cancer. The goal is to see if adding radiation helps shrink the tumor and improve outcomes.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.